MaxCyte (MXCT) Competitors GBX 266 +4.00 (+1.53%) (As of 12:32 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades MXCT vs. PAY, LOOK, RSG, OCN, CSN, TRMR, HUR, ACRL, TRU, and TUNGShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include PayPoint (PAY), Lookers (LOOK), Resolute Mining (RSG), Ocean Wilsons (OCN), Chesnara (CSN), Tremor International (TRMR), Hurricane Energy (HUR), Accrol Group (ACRL), TruFin (TRU), and Tungsten (TUNG). These companies are all part of the "business services" industry. MaxCyte vs. PayPoint Lookers Resolute Mining Ocean Wilsons Chesnara Tremor International Hurricane Energy Accrol Group TruFin Tungsten PayPoint (LON:PAY) and MaxCyte (LON:MXCT) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Is PAY or MXCT more profitable? PayPoint has a net margin of 11.98% compared to MaxCyte's net margin of -77.97%. PayPoint's return on equity of 30.65% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets PayPoint11.98% 30.65% 6.54% MaxCyte -77.97%-15.33%-11.07% Does the MarketBeat Community prefer PAY or MXCT? PayPoint received 193 more outperform votes than MaxCyte when rated by MarketBeat users. However, 68.92% of users gave MaxCyte an outperform vote while only 61.68% of users gave PayPoint an outperform vote. CompanyUnderperformOutperformPayPointOutperform Votes34661.68% Underperform Votes21538.32% MaxCyteOutperform Votes15368.92% Underperform Votes6931.08% Which has better earnings and valuation, PAY or MXCT? PayPoint has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than PayPoint, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPayPoint£297.90M1.90£35.69M£0.491,602.04MaxCyte£45.44M6.15-£35.43M-£0.26-1,023.08 Does the media refer more to PAY or MXCT? In the previous week, PayPoint had 2 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for PayPoint and 1 mentions for MaxCyte. PayPoint's average media sentiment score of 1.22 beat MaxCyte's score of 0.00 indicating that PayPoint is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PayPoint 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, PAY or MXCT? PayPoint has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Do analysts prefer PAY or MXCT? PayPoint presently has a consensus target price of GBX 675, indicating a potential downside of 14.01%. Given PayPoint's stronger consensus rating and higher possible upside, research analysts plainly believe PayPoint is more favorable than MaxCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PayPoint 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MaxCyte 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in PAY or MXCT? 37.4% of PayPoint shares are held by institutional investors. Comparatively, 70.5% of MaxCyte shares are held by institutional investors. 31.4% of PayPoint shares are held by company insiders. Comparatively, 1.5% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryPayPoint beats MaxCyte on 14 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£279.54M£2.04B£5.10B£1.40BDividend YieldN/A2.49%5.04%11.79%P/E Ratio-1,023.08212.3295.121,555.80Price / Sales6.15202.001,217.30210,506.32Price / Cash1.9716.0539.4933.06Price / Book1.263.356.972.81Net Income-£35.43M£70.94M£118.73M£153.14M7 Day Performance-4.66%-2.27%-1.22%-0.48%1 Month Performance-9.96%-2.32%-3.07%7.21%1 Year Performance-24.00%26.00%32.52%93.59% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyteN/AGBX 266+1.5%N/A-22.4%£279.54M£45.44M-1,023.0880News CoverageGap UpHigh Trading VolumePAYPayPoint0.9559 of 5 starsGBX 785-6.0%GBX 675-14.0%+57.5%£566.22M£297.90M1,657.141,260Dividend IncreasePositive NewsHigh Trading VolumeLOOKLookersN/AN/AN/AN/A£503.22M£4.48B811.2538RSGResolute Mining2.3113 of 5 starsGBX 21.60-3.1%GBX 39+80.6%+12.7%£460.08M£643.08M1,680.0040,000Gap DownHigh Trading VolumeOCNOcean WilsonsN/AGBX 1,230+1.7%N/A+6.6%£434.93M£519.35M913.5374,200News CoverageCSNChesnaraN/AGBX 252.50+1.0%N/A-6.9%£381.15M£410.30M8,333.335,700News CoverageTRMRTremor InternationalN/AGBX 201.20+1.8%N/A+37.7%£293.13M£343.77M-1,829.09167HURHurricane EnergyN/AGBX 7.79+4.8%N/A+0.0%£155.02M£275.50M194.755,660High Trading VolumeACRLAccrol GroupN/AGBX 39+0.5%N/AN/A£124.36M£221.16M-3,900.00456TRUTruFinN/AGBX 66.70+0.3%N/A+17.0%£70.61M£36.48M2,203.3312,200TUNGTungstenN/AGBX 54.60-0.5%N/A+0.0%£69.09M£36.39M-19.50200News Coverage Related Companies and Tools Related Companies PayPoint Competitors Lookers Competitors Resolute Mining Competitors Ocean Wilsons Competitors Chesnara Competitors Tremor International Competitors Hurricane Energy Competitors Accrol Group Competitors TruFin Competitors Tungsten Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:MXCT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
